Search

everythinglearnresearchcommunity

for

Search:↓

Higher CRHR1 levels in AA patients lead to increased inflammation.

Long-term use of certain prostate drugs can worsen erectile dysfunction by changing penile tissue, especially in rats with high blood pressure.

The document suggests using trazodone and clomiphene to treat sexual dysfunction caused by post-finasteride syndrome.

Targeting androgen receptor signaling may improve acute myeloid leukemia treatment.

Cepharanthine and berbamine may affect SK channels, influencing their therapeutic effects.

Cyclosporine A may help treat hair loss by blocking a protein that inhibits hair growth.

Roxithromycin, an antibiotic, can increase hair growth and might be used as a treatment for hair loss.

A new topical treatment for hair loss shows promise by targeting androgen receptors.

ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.

These medications for BPH have known risks and may have new side effects.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

Using polymeric micelles to deliver spironolactone topically could improve wound healing in skin affected by glucocorticoids.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

Potassium channel openers are effective in treating heart conditions, high blood pressure, pulmonary diseases, bladder issues, and hair loss, but more selective drugs are needed.

A new mutation in the human glucocorticoid receptor reduces its function and causes resistance to glucocorticoids.

Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.

Some vitamin D analogs can thicken skin and reduce pore size like a common acne treatment, with one analog also affecting skin growth factors.

The structure of SRD5A reveals how it reduces steroids, aiding drug design for related health conditions.

Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.

RXRα is crucial for proper immune response and links diet to immune function.

The review suggests there's no agreed treatment for Frontal Fibrosing Alopecia, but hydroxychloroquine and 5a-reductase inhibitors are most effective. New treatments like platelet-rich plasma and LED light could help if standard treatments fail.

Ritlecitinib works well and is safe for treating alopecia areata.

Retinoids increase steroid sulfatase activity in leukemia cells through RARα/RXR and involves certain pathways like phosphoinositide 3-kinase and ERK-MAP kinase.

Targeting amphiregulin may improve treatment for fibrosis and cancer.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

ALRN-6924 may prevent hair loss caused by chemotherapy.

Spanlastic formulations improve rivaroxaban's oral anticoagulation efficiency.

5α-reductase inhibitors help treat disorders caused by DHT and have potential for future therapies.

SARM-induced changes in the androgen receptor are specific to each ligand and affect stability and protein interactions.